Making the discoveries that defeat cancer

  • Home »
  • Research »
  • Repository

  • Administrators Login

  • Repository Homepage
  • About the Repository
  • Browse the Repository
  • Search the Repository
  • Contribute an Article
  • Missing Publications
  • Repository Help

Genomic markers of panitumumab resistance including ERBB2/HER2 in a phase II study of KRAS wild-type (wt) metastatic colorectal cancer (mCRC)

Tools
- Tools
+ Tools

Barry, G. S., Cheang, M. C., Chang, H. L., Kennecke, H. F. (2016) Genomic markers of panitumumab resistance including ERBB2/HER2 in a phase II study of KRAS wild-type (wt) metastatic colorectal cancer (mCRC). Oncotarget, 7 (14). pp. 18953-18964. ISSN 1949-2553

[img]
Preview
Text
15106.pdf

Download (3MB) | Preview
Official URL: http://www.impactjournals.com/oncotarget/index.php...

Abstract

A prospective study was conducted to identify biomarkers associated with resistance to panitumumab monotherapy in patients with metastatic colorectal cancer (mCRC). Patients with previously treated, codon 12/13 KRAS wt, mCRC were prospectively administered panitumumab 6mg/kg IV q2weeks. Of 34 panitumumab-treated patients, 11 (32%) had progressive disease at 8 weeks and were classified as non-responders. A Nanostring nCounter-based assay identified a 5-gene expression signature (ERBB2, MLPH, IRX3, MYRF, and KLK6) associated with panitumumab resistance (P = 0.001). Immunohistochemistry and in situ hybridization determined that the HER2 (ERBB2) protein was overexpressed in 4/11 non-responding and 0/21 responding cases (P = 0.035). Two non-responding tumors had ERBB2 gene amplification only, and one demonstrated both ERBB2 amplification and mutation. A non-codon 12/13 KRAS mutation occurred in one panitumumab-resistant patient and was mutually exclusive with ERBB2/HER2 abnormalities. This study identifies a 5-gene signature associated with non-response to single agent panitumumab, including a subgroup of non-responders with evidence of aberrant ERBB2/HER2 signaling. KRAS wt tumors resistant to EGFRi may be identified by gene signature analysis, and the HER2 pathway plays an important role in resistance to therapy.

Item Type: Article
All Authors: Barry, G. S., Cheang, M. C., Chang, H. L., Kennecke, H. F.
Additional Information: ISI Document Delivery No.: DL5TE Times Cited: 0 Cited Reference Count: 43 Barry, Garrett S. Cheang, Maggie C. Chang, Hector Li Kennecke, Hagen F. AMGEN CANADA; BC Cancer Foundation; BC Cancer Agency; Cancer Research UK (CRUK) Core grant [C1491/A15955] This study was supported by AMGEN CANADA, the BC Cancer Foundation and the BC Cancer Agency. Maggie Chon U Cheang is supported by the Cancer Research UK (CRUK) Core grant (Grant number C1491/A15955) to Clinical Trials and Statistics Unit at The Institute of Cancer Research (ICR-CTSU). 0 IMPACT JOURNALS LLC ALBANY ONCOTARGET
Uncontrolled Keywords: mCRC nanostring ERBB2 HER2 EGFR inhibitor resistance ALPHA-B-CRYSTALLIN BREAST-CANCER RAS MUTATIONS TRIAL BRAF CETUXIMAB OVEREXPRESSION SENSITIVITY POPULATION EXPRESSION
Research teams: ICR divisions > Clinical Studies > Clinical Trials & Statistics Unit
Depositing User: Barry Jenkins
Date Deposited: 06 Jun 2016 14:22
Last Modified: 06 Jun 2016 14:27
URI: http://publications.icr.ac.uk/id/eprint/15106

Actions (login required)

View Item View Item
The Royal Marsden - NHS foundation trust